Table 2.
Summary of open clinical trials of rapamycin for treatment of COVID-19 infection (according to clinicaltrials.gov, accessed on 14 February 2021).
| NCT Number | NCT04482712 | NCT04341675 | NCT04461340 |
|---|---|---|---|
| Status | Not yet recruiting | Recruiting | Recruiting |
| Start | January 2021 | 24 April 2020 | 15 August 2020 |
| Title | Effects of mTOR Inhibition with Sirolimus (RAPA) in Patients with COVID-19 to Moderate the Progression of ARDS | Sirolimus Treatment in Hospitalized Patients with COVID-19 Pneumonia | Efficacy and Safety of Sirolimus in COVID-19 Infection |
| Phase | 1/2 | 2 | 2 |
| Number of subjects | 20 | 30 | 40 |
| Age | 60+ | 18+ | 18+ |
| Planned outcomes | Survival rate; Change in Clinical Status assessed by the WHO scale; Change in Clinical Status assessed by the NIAID scale; All-cause mortality; duration of ECMO; Duration of supplemental oxygen; Length of hospital stay; Length of time to SARS-CoV2 negativity. | Proportion of patients who are alive and free from advanced respiratory support measures at day 28; Proportion of patients who require escalation in care; Change over time in study-specific biomarkers (LDH, Ferritin, D-dimer, lymphocyte count); Proportion of patients surviving to hospital discharge; Drug safety profile; Duration of advanced respiratory support; Duration of hospital stay; Time from treatment initiation to death; Time to resolution of fever; Proportion of patients who require initiation of off-label therapies; |
Time to clinical recovery; Viral clearance; Radiological lung extension; drug adverse events; 28 day mortality; Intensive care unit admission rate; Duration of hospital stay; Duration from hospitalization to discharge |
| Location | San Antonio, TX, USA | Chicago, IL, USA; Cincinnati, OH, USA | Faculty of Medicine, Alexandria university, Egypt |
| Last update | 30 November 2020 | 20 May 2020 | 9 September 2020 |